

**Supporting Information**

for

**CATALYTIC ASYMMETRIC RING-OPENING OF  $\sigma$ -SYMMETRIC  
CYCLIC CARBONATES WITH CHIRAL AMINO SULFONAMIDE  
CATALYSTS**

Michiyasu Nakao, Tomomi Shozui, Daisuke Inoue, Takahito Ihara, Syuji Kitaike,

and Shigeki Sano\*

Graduate School of Pharmaceutical Sciences, Tokushima University

Sho-machi, Tokushima 770-8505, Japan

### Enzymatic acetylation of $\sigma$ -symmetric 1,3-diols **15a-c**

To a solution of 1,3-diol **15a** (100 mg, 0.319 mmol) in vinyl acetate (6.38 mL) was added PPL (95.7 mg, 16200 units/mmol) at room temperature. After stirring for 4 h, the reaction mixture was filtered and concentrated in *vacuo*. The residue was purified by column chromatography [Silica Gel 60N: *n*-hexane–AcOEt (1:2)] to afford (*R*)-**16a** (45.4 mg, 40%, 98% ee). The enantiomeric excess of (*R*)-**16a** was determined by HPLC analysis [CHIRALPAK IB, *n*-hexane–2-propanol (4:1), flow rate: 1.0 mL/min; detection: 254 nm;  $t_R$  (major) = 12.62 min,  $t_R$  (minor) = 15.96 min].

#### (*R*)-2-{{[(9*H*-Fluoren-9-yl)methoxy]carbonyl}amino}-3-hydroxypropyl Acetate [(*R*)-**16a**]

White solid; mp 129–131 °C;  $[\alpha]_D^{18} +2.0$  ( $c$  0.32, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  2.10 (s, 3H), 2.27 (brt, 1H), 3.61–3.74 (m, 2H), 3.90–4.00 (m, 1H), 4.22 (brs, 3H), 4.43 (d,  $J$  = 6.5 Hz, 2H), 5.18 (brd, 1H), 7.32 (td,  $J$  = 1.1, 7.4 Hz, 2H), 7.41 (t,  $J$  = 7.4 Hz, 2H), 7.59 (d,  $J$  = 7.4 Hz, 2H), 7.77 (d,  $J$  = 7.5 Hz, 2H); IR (KBr) 3337, 2958, 1716, 1697, 1542, 1273 cm<sup>-1</sup>; HRMS (ESI):  $m/z$  [M + Na]<sup>+</sup> calcd for C<sub>20</sub>H<sub>21</sub>NO<sub>5</sub>Na: 378.1317; found: 378.1325.

#### (*R*)-2-{{(Benzyloxy)carbonyl}amino}-3-hydroxypropyl Acetate [(*R*)-**16b**]

99% ee, HPLC analysis [CHIRALCEL OJ-H, *n*-hexane–2-propanol (2:1), flow rate: 1.0 mL/min; detection: 254 nm;  $t_R$  (major) = 12.84 min,  $t_R$  (minor) = 10.59 min].

White solid; mp 48–50 °C;  $[\alpha]_D^{17} +1.5$  ( $c$  1.00, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  2.07 (s, 3H), 2.28 (brs, 1H), 3.62–3.73 (m, 2H), 4.00 (brs, 1H), 4.22 (d,  $J$  = 5.7 Hz, 2H), 5.11 (s, 2H), 5.18 (brs, 1H), 7.31–7.39 (m, 5H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  20.8, 51.6, 61.7, 62.9, 67.1, 128.1, 128.2, 128.6, 136.2, 156.3, 171.4; IR (KBr) 3341, 1715, 1693, 1543, 1269, 1036 cm<sup>-1</sup>; HRMS (ESI):  $m/z$  [M + Na]<sup>+</sup> calcd for C<sub>13</sub>H<sub>17</sub>NO<sub>5</sub>Na: 290.1004; found: 290.1003.

#### (*R*)-2-[(*tert*-Butoxycarbonyl)amino]-3-hydroxypropyl Acetate [(*R*)-**16c**]

100% ee, HPLC analysis [CHIRALPAK AD-H, *n*-hexane–EtOH (5:1), flow rate: 1.0 mL/min; detection: 220 nm;  $t_R$  (major) = 6.52 min].

Pale yellow oil;  $[\alpha]_D^{17} +5.1$  ( $c$  1.00, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  1.45 (s, 9H), 2.09 (s, 3H), 2.39 (brs, 1H), 3.60–3.71 (m, 2H), 3.88 (brs, 1H), 4.21 (d,  $J$  = 5.7 Hz, 2H), 4.94 (brs, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  20.8, 28.4, 51.1, 62.0, 63.1, 80.0, 155.8, 171.4; IR (neat) 3366, 2979, 1694, 1525, 1392, 1367, 1245 cm<sup>-1</sup>; HRMS (ESI):  $m/z$  [M + Na]<sup>+</sup> calcd for C<sub>10</sub>H<sub>19</sub>NO<sub>5</sub>Na: 256.1161; found: 256.1154.

### Synthesis of (*S*)-**17a-c** by Cbz protection of (*R*)-**16a-c**

To a solution of (*R*)-**16a** (34.0 mg, 0.0957 mmol, 98% ee) and pyridine (46.0  $\mu$ L, 0.574 mmol) in anhydrous THF (1 mL) was added CbzCl (41.0  $\mu$ L, 0.287 mmol) at room temperature. After stirring at 50 °C for 20.5 h, 1N HCl (5 mL) was added and then extracted with CHCl<sub>3</sub> (3 x 10 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in *vacuo*. The residue was purified by column chromatography [Silica Gel 60N: *n*-hexane–AcOEt (3:2)] to afford (*S*)-**17a** (16.7 mg, 36%, 97% ee). The enantiomeric excess of (*S*)-**17a** was determined by HPLC analysis [CHIRALPAK IA, *n*-hexane–2-propanol (4:1), flow rate: 1.0 mL/min; detection: 254 nm;  $t_R$  (major) = 14.12 min,  $t_R$  (minor) = 19.94 min].

(*S*)-2-{{[(9*H*-Fluoren-9-yl)methoxy]carbonyl}amino}-3-{{(benzyloxy)carbonyl}oxy}propyl

Acetate [(*S*)-**17a**]

White solid; mp 57–59 °C;  $[\alpha]_D^{19} -4.9$  ( $c$  0.50, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  2.06 (s, 3H), 4.08–4.15 (m, 1H), 4.16–4.26 (m, 4H), 4.27–4.34 (m, 1H), 4.42 (d,  $J$  = 6.5 Hz, 2H), 5.08 (brd, 1H), 5.17 (s, 2H), 7.31 (td,  $J$  = 0.9, 7.4 Hz, 2H), 7.31–7.41 (m, 7H), 7.57 (d,  $J$  = 7.4 Hz, 2H), 7.76 (d,  $J$  = 7.5 Hz, 2H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  20.7, 47.2, 49.1, 62.8, 66.4, 67.0, 70.1, 120.0, 125.0, 127.1, 127.8, 128.5, 128.68, 128.74, 134.8, 141.3, 143.7, 143.8, 154.8, 155.7, 170.6; IR (KBr) 3329,

3069, 2960, 1739, 1688, 1547, 1287  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$   $[\text{M} + \text{Na}]^+$  calcd for  $\text{C}_{28}\text{H}_{27}\text{NO}_7\text{Na}$ : 512.1685; found: 512.1685.

(*S*)-2-[[*(Benzyloxy)*carbonyl]amino]-3-[[*(benzyloxy)*carbonyl]oxy]propyl Acetate [(*S*)-**17b**]

96% ee, HPLC analysis [CHIRALPAK IB, *n*-hexane–2-propanol (4:1), flow rate: 1.0 mL/min; detection: 254 nm;  $t_R$  (major) = 13.00 min,  $t_R$  (minor) = 11.57 min].

White solid; mp 69–71 °C;  $[\alpha]_D^{19}$  –5.1 ( $c$  1.00,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  2.03 (s, 3H), 4.07–4.17 (m, 1H), 4.17–4.26 (m, 3H), 4.26–4.33 (m, 1H), 5.06–5.14 (m, 1H), 5.10 (s, 2H), 5.16 (s, 2H), 7.30–7.42 (m, 10H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  20.7, 49.0, 62.8, 66.4, 67.1, 70.1, 128.2, 128.3, 128.4, 128.56, 128.66, 128.70, 134.9, 136.1, 154.8, 155.7, 170.1; IR (KBr) 3278, 2900, 1750, 1689, 1376, 1278, 1232  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$   $[\text{M} + \text{Na}]^+$  calcd for  $\text{C}_{21}\text{H}_{23}\text{NO}_7\text{Na}$ : 424.1372; found: 424.1359.

(*S*)-3-[[*(Benzyloxy)*carbonyl]oxy]-2-[[*(tert)*-butoxycarbonyl]amino]propyl Acetate [(*S*)-**17c**]

100% ee, HPLC analysis [CHIRALPAK IA, *n*-hexane–2-propanol (6:1), flow rate: 1.0 mL/min; detection: 254 nm;  $t_R$  (major) = 10.80 min].

Colorless oil;  $[\alpha]_D^{19}$  –4.5 ( $c$  1.66,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  1.44 (s, 9H), 2.06 (s, 3H), 4.08–4.23 (m, 4H), 4.23–4.32 (m, 1H), 4.85 (brd, 1H), 5.16 (s, 2H), 7.32–7.43 (m, 5H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  20.7, 28.3, 48.3, 63.0, 66.6, 70.0, 80.1, 128.4, 128.66, 128.70, 134.9, 154.8, 155.1, 170.6; IR (neat) 3365, 2978, 1748, 1715, 1522, 1392, 1367, 1240  $\text{cm}^{-1}$ ; HRMS (ESI):  $m/z$   $[\text{M} + \text{Na}]^+$  calcd for  $\text{C}_{18}\text{H}_{25}\text{NO}_7\text{Na}$ : 390.1529; found: 390.1543.

### Synthesis of (*S*)-**17a-c** by acetylation of (*S*)-**3a-c**

To a solution of (*S*)-**3a** (40.0 mg, 0.0894 mmol, 81% ee) and pyridine (17.2  $\mu\text{L}$ , 0.215 mmol) in anhydrous  $\text{CH}_2\text{Cl}_2$  (0.42 mL) was added  $\text{Ac}_2\text{O}$  (10.1  $\mu\text{L}$ , 0.107 mmol) at room temperature. After

stirring for 22 h, 1N HCl (3 mL) was added and then extracted with CHCl<sub>3</sub> (3 x 5 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in *vacuo*. The residue was purified by column chromatography [Silica Gel 60N: *n*-hexane–AcOEt (3:2)] to afford (*S*)-**17a** (17.6 mg, 40%, 83% ee). The enantiomeric excess of (*S*)-**17a** was determined by HPLC analysis [CHIRALPAK IA, *n*-hexane–2-propanol (4:1), flow rate: 1.0 mL/min; detection: 254 nm; *t*<sub>R</sub> (major) = 14.07 min, *t*<sub>R</sub> (minor) = 19.76 min].

(*S*)-2-{{[(9*H*-Fluoren-9-yl)methoxy]carbonyl}amino}-3-{{(benzyloxy)carbonyl]oxy}propyl  
Acetate [(*S*)-**17a**]

White solid; mp 101–103 °C; [ $\alpha$ ]<sub>D</sub><sup>20</sup> –3.7 (*c* 0.50, CHCl<sub>3</sub>); HRMS (ESI): *m/z* [M + Na]<sup>+</sup> calcd for C<sub>28</sub>H<sub>27</sub>NO<sub>7</sub>Na: 512.1685; found: 512.1668.

(*S*)-2-{{(Benzyloxy)carbonyl]amino}-3-{{(benzyloxy)carbonyl]oxy}propyl Acetate [(*S*)-**17b**]

78% ee, HPLC analysis [CHIRALPAK IB, *n*-hexane–2-propanol (4:1), flow rate: 1.0 mL/min; detection: 254 nm; *t*<sub>R</sub> (major) = 13.00 min, *t*<sub>R</sub> (minor) = 11.50 min].

White solid; mp 66–68 °C; [ $\alpha$ ]<sub>D</sub><sup>17</sup> –3.9 (*c* 1.00, CHCl<sub>3</sub>); HRMS (ESI): *m/z* [M + Na]<sup>+</sup> calcd for C<sub>21</sub>H<sub>23</sub>NO<sub>7</sub>Na: 424.1372; found: 424.1357.

(*S*)-3-{{(Benzyloxy)carbonyl]oxy}2-[(*tert*-butoxycarbonyl)amino]propyl Acetate [(*S*)-**17c**]

70% ee, HPLC analysis [CHIRALPAK IA, *n*-hexane–2-propanol (6:1), flow rate: 1.0 mL/min; detection: 254 nm; *t*<sub>R</sub> (major) = 10.71 min, *t*<sub>R</sub> (minor) = 9.65 min].

Colorless oil; [ $\alpha$ ]<sub>D</sub><sup>18</sup> –2.2 (*c* 1.66, CHCl<sub>3</sub>); HRMS (ESI): *m/z* [M + Na]<sup>+</sup> calcd for C<sub>18</sub>H<sub>25</sub>NO<sub>7</sub>Na: 390.1529; found: 390.1498.